Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $6.69 million. The enterprise value is $658,822.
| Market Cap | 6.69M |
| Enterprise Value | 658,822 |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 1.08 million shares outstanding. The number of shares has increased by 161.67% in one year.
| Current Share Class | 1.08M |
| Shares Outstanding | 1.08M |
| Shares Change (YoY) | +161.67% |
| Shares Change (QoQ) | +2.47% |
| Owned by Insiders (%) | 2.67% |
| Owned by Institutions (%) | 6.49% |
| Float | 1.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 92.80 |
| Forward PS | n/a |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.65
| Current Ratio | 9.65 |
| Quick Ratio | 8.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -123.84 |
Financial Efficiency
Return on equity (ROE) is -99.94% and return on invested capital (ROIC) is -61.66%.
| Return on Equity (ROE) | -99.94% |
| Return on Assets (ROA) | -46.26% |
| Return on Invested Capital (ROIC) | -61.66% |
| Return on Capital Employed (ROCE) | -75.73% |
| Weighted Average Cost of Capital (WACC) | 8.36% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.61M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.71% in the last 52 weeks. The beta is 0.75, so Silo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -34.71% |
| 50-Day Moving Average | 6.31 |
| 200-Day Moving Average | 6.63 |
| Relative Strength Index (RSI) | 50.48 |
| Average Volume (20 Days) | 62,988 |
Short Selling Information
The latest short interest is 16,790, so 1.55% of the outstanding shares have been sold short.
| Short Interest | 16,790 |
| Short Previous Month | 322,795 |
| Short % of Shares Out | 1.55% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 0.59 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$4.84 million in losses. Loss per share was -$6.80.
| Revenue | 72,102 |
| Gross Profit | 8,579 |
| Operating Income | -4.78M |
| Pretax Income | -4.84M |
| Net Income | -4.84M |
| EBITDA | -4.77M |
| EBIT | -4.78M |
| Loss Per Share | -$6.80 |
Balance Sheet
The company has $6.03 million in cash and n/a in debt, with a net cash position of $6.03 million or $5.56 per share.
| Cash & Cash Equivalents | 6.03M |
| Total Debt | n/a |
| Net Cash | 6.03M |
| Net Cash Per Share | $5.56 |
| Equity (Book Value) | 5.68M |
| Book Value Per Share | 5.24 |
| Working Capital | 6.10M |
Cash Flow
| Operating Cash Flow | -3.84M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 11,285 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 11.90% |
| Operating Margin | -6,631.16% |
| Pretax Margin | -6,717.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Silo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -161.67% |
| Shareholder Yield | -161.67% |
| Earnings Yield | -72.39% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | -0.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 3, 2026. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jun 3, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Silo Pharma has an Altman Z-Score of -3.05 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.05 |
| Piotroski F-Score | 3 |